Your shopping cart is currently empty

KRAS G12D Inhibitor 16 is a potent compound targeting the KRAS G12D and its mutation, exhibiting inhibitory activity with IC50 values of 0.7 nM and 0.35 μM, respectively. It is utilized in researching various malignant tumors including pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), and non-small cell lung carcinomas (NSCLC).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $3,980 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $7,650 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $12,560 | 10-14 weeks | 10-14 weeks |
| Description | KRAS G12D Inhibitor 16 is a potent compound targeting the KRAS G12D and its mutation, exhibiting inhibitory activity with IC50 values of 0.7 nM and 0.35 μM, respectively. It is utilized in researching various malignant tumors including pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), and non-small cell lung carcinomas (NSCLC). |
| Targets&IC50 | KRas (G12D):0.7 nM |
| Molecular Weight | 682.59 |
| Formula | C32H39IN6O3 |
| Cas No. | 2648221-12-7 |
| Smiles | C(C1(COC2=NC(=C3C(=N2)CN(CC3)C=4C5=C(C=C(O)C4)C=CC=C5I)N6CC7NC(C6)CC7)CC1)N8CCOCC8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.